简化微分量分布方法,用于在离子辐射疗法中灵活和高效的相对生物有效性计算
Alessio Parisi1, Keith M Furutani1, Chris J Beltran1
1Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, United States of America.
Physics in medicine and biology
|October 31, 2025
概括
简化微剂量分布方法 (AMDM) 允许在离子束疗法中进行灵活和准确的相对生物效率 (RBE) 计算. 这种计算效率高的方法可以避免对不同的RBE模型或细胞线重新运行模拟.
科学领域:
- 医学物理 医学物理
- 辐射瘤学 辐射瘤学
- 计算生物学 计算生物学
背景情况:
- 在离子束疗法当前的临床相对生物有效性 (RBE) 计算使用固定查找表.
- 这限制了灵活性,需要对不同的RBE模型或细胞线进行新的模拟.
研究的目的:
- 在离子束疗法中对精确和灵活的RBE计算进行计算效率高的方法进行基准测试.
- 引入和验证简化微分量分布方法 (AMDM).
主要方法:
- 模拟使用蒙特卡洛PHT代码对各种离子 (H,He,C,O,Ne) 的线性能量分布.
- 使用AMDM量计算RBE,并与完全分布的参考值进行比较.
- 评估了27种RBE模型和细胞系的组合.
主要成果:
- 平均RBE偏差为0.2% (在场内) 和0.3% (在场外).
- 不同的离子和位置的最大偏差低于2%.
- 与参考RBE值相比,AMDM显示了高精度.
结论:
- 在没有新的模拟的情况下,AMDM可以在多个模型和细胞线上进行准确的RBE计算.
- 这为RBE建模和对离子束疗法的回顾性研究提供了显著的灵活性.
- 经过验证的实施方法可以促进临床和研究的整合.
关键词:
在MKMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMM蒙特卡罗的蒙特卡罗是一个非常好的城市.菲特斯 (Phits) 是一个虚拟的东西.在RBE中,RBE就是RBE.离子疗法是一种离子疗法.微剂量测量是微剂量测量的方法.更多相关视频
相关概念视频
Biological Effects of Radiation
17.6K
All radioactive nuclides emit high-energy particles or electromagnetic waves. When this radiation encounters living cells, it can cause heating, break chemical bonds, or ionize molecules. The most serious biological damage results when these radioactive emissions fragment or ionize molecules. For example, α and β particles emitted from nuclear decay reactions possess much higher energies than ordinary chemical bond energies. When these particles strike and penetrate matter, they...
17.6K
Dosage Regimens: Partial Pharmacokinetic Parameters
144
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
144
Bioavailability Study Design: Absolute Versus Relative Bioavailability
286
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
286
Dose Size and Dosing Frequency: Determination Methods
269
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
269
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
395
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
395


